Dossier assessment
Casirivimab/imdevimab (COVID-19) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Casirivimab/imdevimab (COVID-19) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Casirivimab/imdevimab (COVID-19) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults and adolescents from 12 years of age and weighing at least 40 kilograms with COVID-19 who do not require supplemental oxygen and who are at increased risk of their disease becoming severe
- Patients ≥ 18 years: hint of a considerable added benefit
- Patients ≥ 12 to < 18 years: added benefit not proven
Project details
- Project no.
- A22-48
- Commission
- Commission awarded on 15.04.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Casirivimab/imdevimab (post-exposure prophylaxis of COVID-19) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed